Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract

Handbook of Experimental Pharmacology

Volumn 202, Issue , 2011, Pages 527-542

  Ückert, Stefan ^a,b   Kuczyk, Markus A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Urological Research Unit   (Germany)

Author keywords

Cyclic adenosine monophosphate (cyclic AMP); Cyclic guanosine monophosphate (cyclic GMP); Lower urinary tract; Nitric oxide (NO); Pharmacotherapy

Indexed keywords

ALFUZOSIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC NUCLEOTIDE; DOXAZOSIN; GUANYLATE CYCLASE; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN KINASE C; RHO KINASE; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; TAMSULOSIN; VARDENAFIL; VINPOCETINE; CELL RECEPTOR; CYCLIC NUCLEOTIDE DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE INHIBITOR; SOLUBLE GUANYLYL CYCLASE;

ARTICLE; BEDTIME DOSAGE; BLADDER NECK STENOSIS; DETRUSOR MUSCLE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NOCTURIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT OBSTRUCTION; URINARY URGENCY; ANIMAL; DRUG EFFECT; ENZYMOLOGY; FEMALE; MALE; METABOLISM; REVIEW; SECOND MESSENGER; TREATMENT OUTCOME; URINARY TRACT; URINARY TRACT DISEASE;

ANIMALS; CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES; FEMALE; GUANYLATE CYCLASE; HUMANS; MALE; NITRIC OXIDE; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SECOND MESSENGER SYSTEMS; TREATMENT OUTCOME; URINARY TRACT; UROLOGIC DISEASES;

EID: 79952237136     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-16499-6_23     Document Type: Article

References (71)

1. Alm P, Larsson B, Ekblad E, Sundler F, Andersson KE (1993) Immunohistochemical localization of peripheral nitric oxide synthase-containing nerves using antibodies raised against synthesized C- and N-terminal fragments of a cloned enzyme from rat brain. Acta Physiol Scand 148: 421-429 (Pubitemid 23234551)
2. Andersen JT, Ekman P, Wolf H, Beistand HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46: 631-637
3. Andersson KE (1993) Pharmacology of lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev 45: 253-308
4. Andersson KE, Persson K (1993) The L-arginine/nitric oxide pathway and nonadrenergic-noncholinergic relaxation of the lower urinary tract. Gen Pharmacol 24: 833-839
5. Andersson KE, Chapple C, Wein A (2001) The basis for drug treament of the overactive bladder. World J Urol 19: 294-298 (Pubitemid 33777073)
6. Antoni FA (2000) Molecular diversity of cAMP signaling. Front Neuroendocrinol 21: 103-132
7. Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U (1998) The effect of the specific phosphodiesterase 4 inhibitor rolipram on the ureteral peristalsis in vitro and in vivo. J Urol 160: 920-925 (Pubitemid 29479555)
8. Bennett BC, Kruse MN, Roppolo JR, Flood HD, Fraser M, de Groat WC (1995) Neural control of urethral outlet activity in vivo: role of nitric oxide. J Urol 153: 2004-2009
9. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP (2003) BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide dependent penile erection. Urology 61: 464-467 (Pubitemid 36206566)
10. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L (2010) Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 75: 1452-1458
11. Chiricos TN, Sanford E (1996) Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 155: 1311-1316
12. Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63: 1-38
13. Denninger JW, Marletta MA (1999) Guanylate cyclase and the NO/cGMP signalling pathway, Biochim Biophys Acta 1411: 334-350 (Pubitemid 29221959)
14. Ehren I, Iversen H, Jansson O, Adolfsson J, Wiklund NP (1994) Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 44: 683-687
15. Elesber AA, Solomon H, Lennon RJ, Mathew V, Prasad A, Pumper G, Nelson RE, McConnell JP, Lerman LO, Lerman A (2006) Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 27: 824-831.
16. Essayan DM (2001) Cyclic nucleotide phosphodiesterases, J Allerg Clin Immunol 108: 671-680
17. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Philips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97: 3702-3707 (Pubitemid 30183366)
18. Feil R, Gappa N, Rutz M, Schlossmann J, Rose CR, Konnerth A, Brummer S, Kuhbandner S, Hofman F (2002) Functional reconstitution of vascular smooth muscle cells with cGMPdependent protein kinase I isoforms. Circ Res 90: 1080-1086 (Pubitemid 34627906)
19. Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998a) Isolation and characterization of PDE8A, a novel cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246: 570-577 (Pubitemid 28420898)
20. Fisher AD, Smith JF, Pillar JS, St Denis S, Cheng JB (1998b) Isolation and characterization of PDE9A, a novel cGMP-specific phosphodiesterase, J Biol Chem 273: 15559-15564 (Pubitemid 28298168)
21. Friebe A, Müllershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54: 962-967 (Pubitemid 29002038)
22. Gacci M, del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M (2007) Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178: 2040-2043
23. Ganz P (2005) Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 96: 8M-12M
24. Gratzke C, Ückert S, Kedia G, Reich O, Schlenker B, Scitz M, Becker AJ, Stief CG (2007) In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 35: 49-54
25. Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia, Urol Clin North Am 22: 247-261.
26. Gülcer C, Tüzel E, Dogantekin E, Kiziltepe G (2008) Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 80: 181-185
27. Guven EO, Balbay MD, Mete K, Serefoglu EC (2009) Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 41: 287-92
28. Han P, Zhu X, Michaeli T (1997) Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272: 16152-16157 (Pubitemid 27276430)
29. ATP channels reduces contractility of human prostate tissue. Prostate 66: 377-385
30. Hedlund P (2005) Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract: is there a basis for pharmacological targeting of cGMP? World J Urol 23: 362-367
31. Hedlund P, Aszodi A, Pfeifer A, Aim P, Hofman F, Ahmad M, Fassler R, Andersson KE (2000) Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci US A 97: 2349-2354 (Pubitemid 30134072)
32. Hieble JR, Ruffolojr RR (1996) The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hyperplasia: an overview. Pharmacol Res 33: 145-160
33. Ho KM, McMurray G, Brading AF, Noble JG, Ny L, Andersson KE (1998) Nitric oxide synthase in the heterogeneous population of intramural striated muscle fibres of the human membranous urethral sphincter. J Urol 159: 1091-1096 (Pubitemid 28106599)
34. Hobbs AJ (2002) Soluble guanylate cyclase: an old therapeutic target re-visited. Br J Pharmacol 136: 637-640
35. Jacobsen SJ, Guess HA, Panser L, Girman CJ, Chute CG, Oesterling JE, Lieber MM (1993) A population-based study of health care seeking behaviour for treatment of urinary symptoms, Arch. Fam Med 2: 729-735
36. Kalsi JS, Kell PD (2004) Update on the oral treatments for male erectile dysfunction. J Eur Acad Dermatol Venereol 18: 267-274 (Pubitemid 38618320)
37. Kedia GT, Ückert S, Steffenhagen V, Sonnenberg JE, Kuczyk MA (2009) Expression von Phosphodiesterase (PDE)-Isoenzymen in der humanen Urethra - Eine molekularbiologische Studie. Abstract presented at the 3. Nordkongress Urologie, Braunschweig, Germany, 14-16 May 2009
38. Komalavilas P, Lincoln TM (1994) Phosphorylation of the inositol-1, 4, 5-trisphosphate receptor by cyclic GMP-dependent protein kinase. J Biol Chem 269: 8701-8107
39. Kühn R, Ückert S, Stief CG, Truss MC, Lietz B, Bischoff E, Schramm M, Jonas U (2000) Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide dependent pathways. Urol Res 28: 110-115 (Pubitemid 30397413)
40. Lee YC, Martin E, Murad F (2000) Human recombinant soluble guanylyl cyclase: expression, purification, and regulation, Proc Natl Acad Sci USA 97: 10763-10768
41. Lincoln TM, Thompson M, Corn well TL (1988) Purification and characterization of two forms of cyclic GMP-dependent protein kinase from bovine aorta. J Biol Chem 263: 17632-17637
42. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3′,5′-cyclic nucleotide phosphodiesterase. Gene 234: 109-117 (Pubitemid 29294097)
43. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52: 375-414
44. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007a) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077 (Pubitemid 46216352)
45. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007b) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia, J Urol 177: 1401-1407 (Pubitemid 46435965)
46. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD (2003) A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 72: 1015-1025 (Pubitemid 36001981)
47. Moreland RB, Hsieh GC, Nakane M, Miller LN, Chang R, Kolasa T, Sullivan J, Brioni JD (2002) Novel soluble guanylate cyclase activators A-344905 and A-305619 activate sGC in vitro and facilitate penile erection in rats. J Urol 167(suppl 4): 938 (Abstract)
48. Mumtaz FH, Sullivan ME, Thompson CS, Dashwood MR, Naseem KM, Bruckdorfer KR, Mikhailidis DP, Morgan RJ (1999) Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy. J Urol 162: 558-566 (Pubitemid 29434397)
49. Persson K, Pandita RK, Aszodi A, Ahmad M, Pfeifer A, Fassler R, Andersson KE (2000) Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 279: R1112-R1120
50. Reitz A, Bretscher S, Knapp PA, Muntener M, Wefer B, Schurch B (2004) The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans. Eur Urol 45: 367-373 (Pubitemid 38221412)
51. Riffaud JP, Bemarbe J, Giuliano F, Jones R, Jeremy J (2001) Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflamm Res 50(suppl 3):84 (Abstract)
52. Roehrborn CG, Marks LS, Fenter T, Freedman S, Turtle J, Gittleman M, Morril B, Wolford ET (2004) Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia, Urology 63: 709-715 (Pubitemid 38479415)
53. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L (2009) Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 105: 502-507
54. Saighi D, Zerhib M, Thiounn N, Flam T, Conquy S, Jacob L, dall'Ava-Santucci J, Debré B, DinhXuan AT (2000) In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a phosphodiesterase inhibitor. Prog Urol 10: 1161-1168
55. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90: 836-839 (Pubitemid 36693615)
56. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K, Fukunaga Y, Sakaguchi S, Sone M, Yamahara K, Yurugi T, Nakao K (2001) cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 280: 798-805 (Pubitemid 32924500)
57. Smet PJ, Edyvane KA, Jonasvicius J, Marshall VR (1994) Colocalisation of nitric oxide synthase with vasoactive intestinal peptide, neuropeptide Y and thyrosine hydroxylase in nerves supplying the human ureter. J Urol 152: 1292-1296 (Pubitemid 2141160)
58. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A (2002) Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135: 333-343 (Pubitemid 34151165)
59. Stief CG, Ückert S, Truss MC, Becker AJ, Machtens S, Jonas U (1996) A possible role for nitric oxide in the regulation of human ureteral smooth muscle tone in vitro. Urol Res 24: 333-337 (Pubitemid 27022450)
60. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-1244
61. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz I, Ducke B, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A (2001) NO-independent stimulators of soluble guanylate cyclase, Bioorg Med Chem Lett 11: 781-784 (Pubitemid 32230679)
62. Surks HK, Mochizuki N, Kasai Y, Georgescu SP, Tang KM, Ito M, Lincoln TM, Mendelsohn ME (1999) Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase Iα. Science 286: 1583-1587
63. Taher A, Schulz-Knappe P, Meyer M, Truss MC, Forssmann WG, Stief CG, Jonas U (1994) Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol 12: 286-291
64. Truss MC, Ückert S, Stief CG, Kuczyk MA, Jonas U (1996a) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: I. Identification and characterization, Urol Res 24: 123-128 (Pubitemid 26226247)
65. Truss MC, Ückert S, Stief CG, Kuczyk MA, Jonas U (1996b) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle: II. Effect of various PDE-inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro, Urol Res 24: 129-134
66. Truss MC, Stief CG, Ückert S, Becker AJ, Wefer J, Schultheis D, Jonas U (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19: 344-350
67. Ückert S, Küthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-2490
68. Ückert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate, Eur Urol 49: 740-745
69. Ückert S, Sandner P, Sigl K, Ulbrich E, Stief CG, Kuczyk MA (2009) Is there a role of the phosphodiesterase type 5 (PDE5) in the control of detrusor smooth muscle? A functional and molecular biology study. J Urol 181(suppl 4): 152 (Abstract)
70. Waldkirch ES, Ückert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P (2007) Immunohistochemical distribution of cyclic GMP-dependent protein kinase 1 in human prostate tissue. Eur Urol 52: 495-502
71. Werkström V, Svensson A, Andersson KE, Hedlund P (2006) Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 98: 414-423